A first-in-class oral insulin molecule for post-prandial glycaemic control

Biocon has invested in the development of Insulin Tregopil, which mimics the physiological benefits of direct delivery into the portal vein to offer better patient compliance. Studies conducted in Type 1 diabetes, Type 2 diabetes as well as normal healthy volunteers have demonstrated an excellent safety profile for Tregopil, with evidence of significant post-prandial glucose excursion control in Type 2 diabetes patients. A pivotal Phase II/III study in Type 2 diabetes patients in India was initiated in FY18 and is currently ongoing. Likewise, for Type 1 diabetes patients, a multiple ascending dose study is progressing in partnership with U.S.-based JDRF, a leading global organisation funding Type 1 diabetes (T1D) research and advocacy worldwide.